Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 19
---
 reverse stock split.

Concurrently with the
reverse stock split, and in an effort to bring the Depositary Shares price into compliance with NASDAQ’s minimum requirement for
500,000 listed Depositary Shares, on March 27, 2023, we effected a ratio change in the number of our Ordinary Shares represented by the
Depositary Shares from 25 Ordinary Shares per Depositary Share to five Ordinary Shares per Depositary Share. No fractional Depositary
Shares were issued.

| 14 |

Between March 27, 2023
and June 30, 2025, we have issued 95,137,075 Ordinary Shares upon the exercise of pre-funded warrants, Series A Warrants and Series B
Warrants issued in the February Private Placement.

On May 26, 2023, we completed
the closing of a registered direct offering with institutional investors of (1) 166,017,700 Ordinary Shares represented by 1,660 Depositary
Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price of $4,000.00 per warrant, (2)
110,675,600 Ordinary Shares represented by 1,098 Depositary Shares issuable upon the exercise of the Series D warrants, or Series D Warrants,
at an exercise price of $4,000.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 44 Depositary Shares issuable upon the
exercise of warrants issued to the placement agent in the offering at an exercise price of $3,750.00 per warrant, or May 2023 Placement
Agent Warrants.

On June 14, 2023, we held
our June AGM, and our shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication
of pre-emption rights in respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a separate June GM, and our shareholders
passed resolutions to, among other things, (i) re-designate our deferred shares into A deferred shares, and (ii) subdivide our Ordinary
Shares of £0.02 nominal value each into one Ordinary Share of £0.001 nominal value and 19 B deferred shares of £0.001
nominal value each.

On June 20, 2023, we
issued the Series C Warrants, Series D Warrants and May